Abstract:
본 발명은 우수한 항암활성을 가지는 다음 화학식 1로 표시되는 신규 1-[(3-알콕시-6-치환-퀴녹살린-2-일)아미노카르보닐]-4-(헤테로)아릴피페라진 유도체와 약제학적으로 허용 가능한 이의 염, 이 화합물의 제조방법, 그리고 이 화합물의 항암제로서의 용도에 관한 것이다.
상기 화학식 1에서, X 및 Y는 각각 N, 또는 CR 6 이며; R 1 은 C 1 -C 6 의 알콕시기, C 1 -C 6 의 알킬기, 또는 할로겐원자이며, R 2 는 C 1 -C 6 의 알킬기이며; R 3 , R 4 , R 5 , 및 R 6 은 각각 수소원자, C 1 -C 6 의 알콕시기, C 1 -C 6 의 알킬기, C 1 -C 6 의 할로알킬기, C 1 -C 6 의 알킬카르보닐기, 할로겐원자, 시아노기, 또는 니트로기이다. 퀴녹살린, 피페라진, 우레아, 위치선택적, 항암제
Abstract:
본 발명은 RTK(Receptor Tyrosine Kinase; 수용체 티로신 효소) 저해활성이 우수한 다음 화학식 1로 표시되는 6-알킬아미노-2,2'-이중치환-벤조피란 유도체와 이의 이성질체, 및 약제학적으로 허용 가능한 이의 염을 항암제로서 사용하는 용도에 관한 것이다.
상기 화학식 1에서, R 1 , R 2 , R 3 , R 4 , n은 각각 발명의 상세한 설명에서 정의한 바와 같다. 아미노벤조피란, 수용체 티로신 효소, 상피세포, 항암제, RTK
Abstract:
PURPOSE: A pharmaceutical composition containing novel thienopyrimidine derivative for preventing or treating various diabetic diseases is provided to enhance saccharide-dependent insulin secretion and to improve saccharide and lipid metabolism. CONSTITUTION: A thienopyrimidine derivative is denoted by chemical formula 1. A pharmaceutical composition for preventing or treating diabetic diseases contains the thienopyrimidine derivative of chemical formula 1, a pharmaceutically acceptable salt thereof, or solvate thereof as an active ingredient. The pharmaceutical composition is used by oral or parenteral administration. The daily dose of the pharmaceutical composition is 0.01-100 mg/kg.
Abstract:
PURPOSE: A method for preparing triazolylcoumarin derivatives with novel fluorous alkyl groups is provided to enable fixation, fixation monitoring, and organic low molecular compound attachment. CONSTITUTION: A triazolylcoumarin derivative is denoted by chemical formula 1. In chemical formula 1: A, B, and D are alkylene group of 1-6 carbon atoms; a is 5-9 integer; and b is 2-5 integer. A method for preparing the derivative comprises: a step of reacting methyl 7-ethynyl coumarin-4-acetate of chemical formula 2 with azide with the fluorous alkyl group of chemical formula 3 to prepare 7-triazolyl coumarin-4-acetate of chemical formula 4; a step of ester hydrolysis of the compound of chemical formula 4 to prepare a fluorous alkyl group-substituted 7-triazolyl coumarin-4-acetic acid of chemical formula 5; a step of reacting the compound of chemical formula 5 with diamine with a protection group of chemical formula 6 to prepare fluorous alkyl group-substituted 7-triazolyl coumarin-4-acetamide; and a step of deprotecting the compound of chemical formula 7 to prepare triazolylcoumarin of chemical formula 1.
Abstract:
PURPOSE: A 1-(6,7-difluoro-3-methoxyquinoxaline-2-yl)-3-[1-(heteroarylmethyl)piperidine-4-yl]urea derivatives is provided to suppress MCH1R and to prevent and treat obesity without side effects. CONSTITUTION: A 1-(6,7-difluoro-3-methoxyquinoxaline-2-yl)-3-[1-(heteroarylmethyl)piperidine-4-yl]urea derivative is denoted by chemical formula 1. The compound of chemical formula 1 is prepared by reduction alkylation of a compound of chemical formula 5 with heteraryl aldehyde compound of chemical formula 6. A MCH1R inhibitor composition contains the compound of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. A pharmaceutical composition for preventing and treating obesity contains the compound of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient.
Abstract:
PURPOSE: A 2-methyl-2H-chromen-2-carboxamide compound is provided to ensure selective suppression to 11beta-HSD1 enzyme and prevent and treat glucocorticoid regulatory disease. CONSTITUTION: A 2-methyl-2H-chromen-2-carboxamide compound is denoted by chemical formula 1. A pharmaceutical composition contains the 2-methyl-2H-chromen-2-carboxamide compound. The pharmaceutical composition is used for treating and preventing type 1 and 2 diabetes, injured glucose resistance, hyperlipidemia or hypertension. The 2-methyl-2H-chromen-2-carboxamide compound in which an amide is induced is obtained by condensing R1-substituted 2-methyl-2H-chromen-2-carboxy acid compound of chemical formula 2 with amine compound(NHR^2R^3).
Abstract translation:目的:提供2-甲基-2H-色烯-2-甲酰胺化合物,以确保对11beta-HSD1酶的选择性抑制,并预防和治疗糖皮质激素调节性疾病。 构成:2-甲基-2H-色烯-2-甲酰胺化合物由化学式1表示。药物组合物含有2-甲基-2H-色烯-2-甲酰胺化合物。 药物组合物用于治疗和预防1型和2型糖尿病,葡萄糖耐量受损,高脂血症或高血压。 通过将化学式2的R1取代的2-甲基-2H-色烯-2-羧酸化合物与胺化合物(NHR 2 R 2) ^ 3)。
Abstract:
PURPOSE: A 2-(2-amido methyl)-2-methyl-2H-benzypyrane compound is provided to ensure selective suppression to 11 beta-HSD 1 enzyme and to prevent and treat clucocorticoid regulatory diseases. CONSTITUTION: A 2-(2-amido methyl)-2-methyl-2H-benzopyrane compound is denoted by chemical formula 1. The 2-(2-amido methyl)-2-methyl-2H-benzopyrane compound is 3-methoxy-N-methyl-N-[(2-methyl-8-nitro-2H-chromen-2-yl)methyl]benzamide or 3-chloro-N-[(2,6-dimethyl-2H-chromen-2-yl)methyl]-N-methylbenzamide. A pharmaceutical composition contains the 2-(2-amido methyl)-2-methyl-2H-benzopyrane compound and prevents and treats impaired glucose tolerance(IGT), type 1 and 2 diabetes, insulin resistance, dyslipidemia or hypertension.